7 research outputs found
Circulating microRNA Profiles in Patients with Type-1 Autoimmune Hepatitis
<div><p>Recent studies have demonstrated that micro (mi)RNA molecules can be detected in the circulation and can serve as potential biomarkers of various diseases. This study used microarray analysis to identify aberrantly expressed circulating miRNAs in patients with type 1 autoimmune hepatitis (AIH) compared with healthy controls. Patients with well-documented and untreated AIH were selected from the National Hospital Organization (NHO)-AIH-liver-network database. They underwent blood sampling and liver biopsy with inflammation grading and fibrosis staging before receiving treatment. To further confirm the microarray data, circulating expression levels of miR-21 and miR-122 were quantified by real-time quantitative polymerase chain reaction in 46 AIH patients, 40 patients with chronic hepatitis C (CHC), and 13 healthy controls. Consistent with the microarray data, serum levels of miR-21 were significantly elevated in AIH patients compared with CHC patients and healthy controls. miR-21 and miR-122 serum levels correlated with alanine aminotransferase levels. Circulating levels of miR-21 and miR-122 were significantly reduced in AIH patients with liver cirrhosis, and were inversely correlated with increased stages of fibrosis. By contrast, levels of circulating miR-21 showed a significant correlation with the histological grades of inflammation in AIH. We postulate that aberrantly expressed serum miRNAs are potential biomarkers of AIH and could be implicated in AIH pathogenesis. Alternations of miR-21 and miR-122 serum levels could reflect their putative roles in the mediation of inflammatory processes in AIH.</p></div
Distribution of HLA-DR alleles distribution in patients with type-1 AIH.
<p>HLA-DRB1 allele was assessed by cis-square test. The probability values were corrected (<i>Pc</i>) for multiple testing (Bonferroni correction).</p
STAT4 rs7574865 polymorphism in patients with type-1 AIH without other autoimmune diseases.
<p>Abbreviation: AIH; autoimmune hepatitis, OR; odds ratio, CI; confidence interval, STAT4; signal transducer and activator or transcription.</p>a<p>Genotype frequencies were determined by χ2 test using 2×3 contingency tables between patients with AIH and healthy controls. Allele frequencies were determined by χ2 test using 2×2 contingency tables between patients with AIH and healthy controls.</p
STAT4 rs7582694 polymorphism in patients with type-1 AIH and controls.
<p>Abbreviation: AIH; autoimmune hepatitis, OR; odds ratio, CI; confidence interval, STAT4; signal transducer and activator or transcription.</p>a<p>Genotype frequencies were determined by χ2 test using 2×3 contingency tables between patients with AIH and healthy controls. Allele frequencies were determined by χ2 test using 2×2 contingency tables between patients with AIH and healthy controls.</p
Differentially expression miRNAs between control and AIH.
<p>Differentially expression miRNAs between control and AIH.</p
Baseline Characteristics of 46 Japanese AIH Type 1 Patients.
<p>AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphate; IgG, immunoglobulin G; ANA, anti-nuclear antibody; ASMA, anti-smooth muscle antibody; IQR, interquartile range; IAIHG, International Autoimmune Hepatitis Group.</p
Baseline characteristics of type-1 AIH patients.
<p>Abbreviations: AIH; autoimmune hepatitis, AST; aspartate aminotransferase, ALT; alanine aminotransferase, ALP; alkaline phosphate, IgG; immunoglobulin G, ANA; anti-nuclear antibody, ASMA; anti-smooth muscle antibody, UDCA; ursodeoxy cholic acid, Aza; azathioprine. Data are expressed as number (percentage) or mean ± standard deviations.</p